Breast Cancer

Experts review and share their perspectives on key findings in breast cancer presented at the 2019 SABCS.

Share

Program Content

Activities

  • 2019 SABCS Preview
    A Look Ahead to the 2019 SABCS Meeting
    Clinical Thought
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2019

    Expires: December 08, 2020

  • CT Insights: SABCS 2019
    New Developments in Chemotherapy-Based Treatment for Breast Cancer: Insights From SABCS 2019
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 27, 2020

    Expires: January 25, 2021

  • Key HER2+ Studies: SABCS 2019
    I’m Excited About New Agents for HER2+ Breast Cancer From SABCS 2019! Here’s Why.
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 13, 2020

    Expires: January 11, 2021

  • HR+ BC Insights: SABCS 2019
    New Developments in HR-Positive/HER2-Negative Breast Cancer: Insights From SABCS 2019
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 31, 2020

    Expires: January 29, 2021

  • SABCS 2019: New Insights in BC
    New Insights in Breast Cancer: Independent Conference Coverage of SABCS 2019
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 02, 2020

    Expires: March 01, 2021

Activities

HER2CLIMB: Tucatinib in HER2+ MBC
HER2CLIMB: Phase II Study of Tucatinib Plus Trastuzumab and Capecitabine in Previously Treated HER2-Positive Metastatic Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2019

Expires: December 14, 2020

SOPHIA 2nd Interim OS Analysis
SOPHIA: Second Interim OS Analysis of Margetuximab + CT vs Trastuzumab + CT for HER2+ MBC After Previous HER2 Therapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2019

Expires: December 18, 2020

DESTINY-Breast01
DESTINY-Breast01: Phase II Study of Trastuzumab Deruxtecan (DS-8201a) in HER2+ Advanced Breast Cancer Previously Treated With T-DM1
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2019

Expires: December 16, 2020

APHINITY: CT + Trastuzumab/Pertuzumab Updated OS
APHINITY: Interim OS Analysis of Adjuvant CT Plus Trastuzumab With vs Without Pertuzumab for Patients With HER2+ EBC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2019

Expires: December 14, 2020

ATEMPT: T-DM1 vs TH in Stage I EBC
Phase II ATEMPT: Analysis of Adjuvant Trastuzumab Emtansine (T-DM1) vs Paclitaxel Plus Trastuzumab in Patients With Stage I HER2-Positive Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2019

Expires: December 17, 2020

PEARL: Palbociclib + ET vs CAPE in HR+ MBC
PEARL: Palbociclib + Endocrine Therapy vs Capecitabine in Postmenopausal Women With HR+/HER- MBC and Previous AI Therapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2019

Expires: December 18, 2020

KEYNOTE-522: pCR by Subgroups
KEYNOTE-522 Study of Neoadjuvant Pembrolizumab vs Placebo in Combination With Chemotherapy for Early-Stage TNBC: Subgroup Analysis of pCR
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2019

Expires: December 17, 2020

plasmaMATCH: ctDNA to Direct Tx in Adv BC
plasmaMATCH (CRUK/15/010): Evaluation of Circulating Tumor DNA Testing to Direct Targeted Therapies in Patients with Advanced Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2019

Expires: December 18, 2020

NSABP B-42 10-Yr Follow-up
NSABP B-42 10-Yr Follow-up: Extended Adjuvant Letrozole After Previous Adjuvant AI Therapy in Postmenopausal Women With HR+ Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2019

Expires: December 17, 2020

Oral vs IV Paclitaxel in MBC
Oral Paclitaxel With P-Glycoprotein Pump Inhibitor Encequidar vs Intravenous Paclitaxel in Metastatic Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2019

Expires: December 18, 2020

INFORM Neoadjuvant Trial
INFORM: Randomized Phase II Study of Neoadjuvant Cisplatin vs AC in Newly Diagnosed Breast Cancer With Germline BRCA Mutations
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2019

Expires: December 15, 2020

T-DXd and QTc/PK in MBC
Phase I Study to Assess the Effect of Trastuzumab Deruxtecan on QTc Interval and Pharmacokinetics in HER2-Expressing Metastatic or Unresectable Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2019

Expires: December 18, 2020

Neratinib for <i>HER2</i>-mutant ABC
plasmaMATCH Cohort B: Neratinib ± Fulvestrant for Patients With HER2 Mutation–Positive Advanced Breast Cancer as Identified by ctDNA Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2019

Expires: December 15, 2020

Neratinib in HER2+ MBC
Impact of Neratinib on CNS Metastases in Patients With HER2-Positive Metastatic Breast Cancer: Analysis of Data From Phase II/III Trials
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2019

Expires: December 18, 2020

CONTROL: Neratinib-Associated Diarrhea
CONTROL: Phase II Trial of Antidiarrheal Prophylaxis or Neratinib Dose Escalation for Neratinib-Associated Diarrhea in Patients With HER2+ Early BC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2019

Expires: December 14, 2020

Neoadj CT ± Atezo in TNBC
NeoTRIPaPDL1 Michelangelo: Neoadjuvant Chemotherapy ± Atezolizumab in Early, High-Risk and Locally Advanced TNBC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Faculty

cover img faculity

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

cover img faculity

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen